Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 December 2024 | Story Martinette Brits | Photo Stephen Collett
Dr Francois Jacobs
Dr Francois Jacobs received his Doctor of Philosophy degree in Chemistry on Monday, 9 December.

Dr Francois Jacobs, a 30-year-old PhD graduate, has recently returned from an intensive training workshop in Harwell, Oxford, courtesy of the David Blow Bursary. This prestigious award recognises outstanding African researchers making significant contributions to macromolecular crystallography.

Dr Jacobs earned his Doctor of Philosophy degree in Chemistry on Monday, 9 December. While earning a PhD by the age of 30 was not part of his initial plan, he always aspired to pursue higher education. “From a young age, I had a strong desire to study at university. Once I got there, my ambition shifted towards obtaining a PhD,” he says, reflecting on the journey that led to this remarkable achievement.

Groundbreaking research on cancer and antibiotics

Dr Jacobs’ research addresses some of the most pressing health challenges of our time: cancer and antibiotic resistance. Using crystallography, he investigates the interactions between newly developed anticancer and antibacterial compounds and biological structures such as proteins at the atomic level. This work is vital in combating the growing threat of antibiotic-resistant bacterial infections and advancing cancer treatments.

"For me, it's about seeing humans thrive and reducing the suffering caused by illness," he explains. "I lost my grandmother to cancer, and I hope my work can spare someone else’s loved one from a similar loss."

Prestigious workshop with global experts

The "DLS-CCP4 Data Collection and Structure Solution Workshop," hosted by Diamond Light Source, offered Dr Jacobs an unparalleled opportunity to learn from leading experts in macromolecular crystallography. The workshop covered critical skills such as growing protein and DNA crystals, preventing degradation during data collection, and processing complex data. Participants also gained insights directly from the engineers and scientists behind the facility’s cutting-edge software and synchrotron technology.

“It was an incredible opportunity to learn from some of the brightest minds in the field,” says Dr Jacobs. “Not only did I acquire new skills, but I also forged new collaborations with potential research partners who can help take my work to the next level.”

The David Blow Bursary, which enabled Dr Jacobs to attend this workshop, is awarded to  African researchers conducting impactful macromolecular crystallography studies.

"This training has been transformative," he adds. "It is a fantastic experience for any aspiring researcher, and I’m grateful to have had the chance to learn from these experts. Many researchers who attend workshops like this go on to work at the Diamond Light Source itself. I am eager to see where this training will take me."

A vision for the future

As Dr Jacobs continues his research, he remains driven by the hope that his work will lead to life-saving advancements in healthcare. “I want my research to provide hope and solutions for individuals battling cancer and bacterial infections,” he says.

His achievements exemplify the transformative power of education, research, and collaboration, and his story serves as an inspiration to aspiring researchers across Africa. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept